How are energy investors positioned?
Lantern Pharma Inc . (NASDAQ:LTRN), a small-cap biotech company with a market capitalization of $32.8 million, has reported a series of stock sales by major shareholders, totaling $168,418. The transactions, disclosed in a recent SEC filing, occurred over three days from May 27 to May 29, 2025. The sales involved multiple funds associated with Bios Partners, including Bios Fund I QP, LP, Bios Fund I, LP, and others. According to InvestingPro analysis, while the company maintains strong liquidity with a current ratio of 4.86, it faces challenges with rapid cash burn.
The shares were sold at prices ranging from $2.87 to $3.05. Specifically, on May 27, shares were sold at a weighted average price of $3.05, while on May 28, the average price was $2.87. On May 29, the shares were sold at an average of $3.03.
Following these transactions, the funds collectively hold a significant number of shares, with Bios Fund I QP, LP retaining 207,422 shares and Bios Fund I, LP holding 354,630 shares, among others. The transactions reflect the ongoing management of holdings by these key investors in Lantern Pharma.
In other recent news, Lantern Pharma Inc. reported a narrower net loss for Q1 2025, emphasizing cost management and innovation in drug development. The company reduced its net loss to $4.5 million, or $0.42 per share, compared to $5.4 million in the same period last year. Lantern Pharma’s cash position stands at $19.7 million, providing operational runway through May 2026. The company is advancing its clinical trials for LP-184 and LP300, with significant milestones anticipated in 2025. Lantern’s AI platform, RADAR, continues to enhance its competitive edge in precision oncology. Additionally, Lantern Pharma unveiled promising preclinical data for its drug candidate LP-184, targeting a rare pediatric brain cancer, ATRT, with plans for a pediatric clinical trial between late 2025 and early 2026. The drug has shown potential to extend survival in mouse models and has received FDA designations for its therapeutic potential. These developments underscore Lantern Pharma’s strategic focus on leveraging AI and clinical advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.